(Total Views: 57)
Posted On: 02/05/2025 3:43:35 PM
Post# of 124
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug Development
Annovis Bio (NYSE: ANVS), a late-stage clinical drug company focused on neurodegenerative diseases, announced the closing of its underwritten public offering, raising $21 million in gross proceeds. The offering included 5.25 million shares of common stock and warrants at a combined price of $4.00 per share, with warrants exercisable at $5.00 per share for five years. The company plans to use the funds primarily for the continued Phase 3 development of its lead Alzheimer’s drug, Buntanetap, as well as for working capital and corporate purposes. ThinkEquity acted as the sole book-running manager.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS), a late-stage clinical drug company focused on neurodegenerative diseases, announced the closing of its underwritten public offering, raising $21 million in gross proceeds. The offering included 5.25 million shares of common stock and warrants at a combined price of $4.00 per share, with warrants exercisable at $5.00 per share for five years. The company plans to use the funds primarily for the continued Phase 3 development of its lead Alzheimer’s drug, Buntanetap, as well as for working capital and corporate purposes. ThinkEquity acted as the sole book-running manager.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Scroll down for more posts ▼
